Sep 13, 2023 / 04:00PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst
All right, let's hit it. Good afternoon, everyone. My name is Arthur He, senior biotech analyst at H.C. Wainwright. Thanks for joining us to have a conversation with Dr. Peter Luo, the Chairman, CEO, and the Co-Founder of Adagene.
Adagene is a clinical-stage biopharmaceutical company focused on develop a novel antibody-based cancer therapy based on its proprietary platform, which including NEObody, POWERbody, and the SAFEbody. So the company currently has four clinical-stage assets and a number of preclinical programs. To discuss this program and the development strategy, I'd like to invite Peter to this conversation. Peter, thanks for coming down to talk to our audience.
Peter Luo - Adagene Inc. - Chairman, CEO, Co-Founder & President of R&D
Thanks, Arthur.
Arthur He - H.C. Wainwright & Co., LLC - Analyst
So just to help set the stage for our audience, could you give us an overview about the Adagene pipeline right now?
Peter
Adagene Inc at HC Wainwright Investment Conference - New York Transcript
Sep 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers